NIH Conferences
15 September 1998

Multiple Endocrine Neoplasia Type 1: Clinical and Genetic Topics

Publication: Annals of Internal Medicine
Volume 129, Number 6

Abstract

Multiple endocrine neoplasia type 1 (MEN1) consists of benign, and sometimes malignant, tumors (often multiple in a tissue) of the parathyroids, enteropancreatic neuroendocrine system, anterior pituitary, and other tissues.Skin angiofibromas and skin collagenomas are common. Typically, MEN1 tumors begin two decades earlier than sporadic tumors. Because of tumor multiplicity and the tendency for postoperative tumor recurrence, specialized methods have been developed for preoperative and intraoperative localization of many MEN1-associated tumors.
The MEN1 gene was recently isolated by positional cloning.This strategy progressively narrows the size of the candidate MEN1 gene interval on the chromosome and then finds and tests many or, if needed, all genes within that interval. The MEN1 gene was finally identified because it was the one gene that contained mutations in most DNAs from a test panel of MEN1 cases.
It has been suggested that MEN1, like many hereditary cancer syndromes, is caused by mutation in a tumor suppressor gene that contributes to neoplasia when both gene copies in a tumor precursor cell have been sequentially inactivated (“two-hit” oncogenesis mechanism). Germline MEN1 mutations were found in most families with MEN1 and in most cases of sporadic MEN1. In addition, the MEN1 gene was the gene most likely to show acquired mutation in several sporadic or nonhereditary tumors-parathyroid adenomas, gastrinomas, insulinomas, and bronchial carcinoids. Most germline or acquired MEN1 mutations predicted truncation (and thus likely inactivation) of the encoded protein, supporting expectations for the “first hit” to a tumor suppressor gene. Testing for MEN1 germline mutation is possible in a research setting. Candidates for MEN1 mutation testing include patients with MEN1 or its phenocopies and first-degree relatives of persons with MEN1.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Marx SJ. Multiple endocrine neoplasia type 1. In: Vogelstein B, Kinzler KW, eds. The Genetic Basis of Human Cancer. New York: McGraw-Hill; 1998:489-506.
2.
Eng C. Seminars in medicine of the Beth Israel Hospital, Boston. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease. N Engl J Med. 1996; 335:943-51.
3.
Erdheim J. Zur normalen und pathologischen Histologie der glandula Thyroidea, Parathyroidea und Hypophysis. Beitr Pathol Anat. 1903; 33:1-234.
4.
Rossier PH, Dressler M. Familiare Erkrangung innersekretorischer drusen kombiniert mit Ulcuskrankheit. Schweiz Med Wochenschr. 1939; 69:985-90.
5.
Schmid JR, Labhart A, Rossier PH. Relationship of multiple endocrine adenomas to the syndrome of ulcerogenic islet cell adenomas (Zollinger-Ellison): occurrence of both syndromes in one family. Am J Med. 1961; 31:343-53.
6.
Wermer P. Genetic aspects of adenomatosis of endocrine glands. Am J Med. 1954; 16:363-71.
7.
Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971; 68:820-3.
8.
Larsson C, Skogseid B, Oberg K, Nakamura Y, Nordenskjold M. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature. 1988; 332:85-7.
9.
Friedman E, Sakaguchi K, Bale AE, Falchetti A, Streeten E, Zimering MB, et al. Clonality of parathyroid tumors in familial multiple endocrine neoplasia type 1. N Engl J Med. 1989; 321:213-8.
10.
Thakker RV, Bouloux P, Wooding C, Chotai K, Broad PM, Spurr NK, et al. Association of parathyroid tumors in multiple endocrine neoplasia type 1 with loss of alleles on chromosome 11. N Engl J Med. 1989; 321:218-24.
11.
Metz DC, Jensen RT, Bale AE, Skarulis MC, Eastman RC, Nieman L, et al. Multiple endocrine neoplasia type 1: clinical features and management. In: Bilezikian JP, Marcus R, Levine MA, eds. The Parathyroids: Basic and Clinical Concepts. New York: Raven Pr; 1994:591-646.
12.
Farid NR, Buehler S, Russell NA, Maroun FB, Allerdice P. Prolactinomas in familial multiple endocrine neoplasia syndrome type 1. Relationship to HLA and carcinoid tumors. Am J Med. 1980; 69:874-80.
13.
Petty EM, Green JS, Marx SJ, Taggart T, Farid N, Bale AE. Mapping the gene for hereditary hyperparathyroidism and prolactinoma (MENIBurin) to chromosome 11q: evidence for a founder effect in patients from Newfoundland. Am J Hum Genet. 1994; 54:1060-6.
14.
Akerstrom G. Management of carcinoid tumors of the stomach, duodenum, and pancreas. World J Surg. 1996; 20:173-82.
15.
Maton PN, Gardner JD, Jensen RT. Cushing's syndrome in patients with the Zollinger-Ellison syndrome. N Engl J Med. 1986; 315:1-5.
16.
Dong Q, Debelenko LV, Chandrasekharappa SC, Emmert-Buck MR, Zhuang Z, Guru SC, et al. Loss of heterozygosity at 11q13: analysis of pituitary tumors, lung carcinoids, lipomas, and other uncommon tumors in subjects with familial multiple endocrine neoplasia type 1. J Clin Endocrinol Metab. 1997; 82:1416-20.
17.
Skosgeid B, Larsson C, Lindgren PG, Kvanta E, Rastad J, Theodorsson E, et al. Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1. J Clin Endocrinol Metab. 1992; 75:76-81.
18.
Darling TN, Skarulis MC, Steinberg SM, Marx SJ, Spiegel AM, Turner M. Multiple facial angiofibromas and collagenomas in patients with multiple endocrine neoplasia type 1. Arch Dermatol. 1997; 133:853-7.
19.
Pack S, Turner ML, Zhuang Z, Vortmeyer A, Boni R, Skarulis M, et al. Cutaneous tumors in patients with multiple endocrine neoplasia type 1 show allelic deletion of the MEN1 gene. J Invest Dermatol. 1998; 11:438-40.
20.
Mallette LE, Bilezikian JP, Heath DA, Aurbach GD. Primary hyperparathyroidism: clinical and biochemical features. Medicine (Baltimore). 1974; 53:127-46.
21.
Fraker DL, Jensen RT. Pancreatic endocrine tumors. In: DeVita DT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 5th ed. Philadelphia: Lippincott-Raven; 1997:1678-704.
22.
Scheiterhauer BW, Laws ER Jr, Kovacs K, Horvath E, Randall RV, Carney AJ. Pituitary adenomas of the multiple endocrine neoplasia type I syndrome. Semin Diagn Pathol. 1987; 4:205-11.
23.
Service FJ, McMahon MM, O'Brien PC, Ballard DJ. Functioning insulinoma-incidence, recurrence, and long-term survival of patients: a 60 year study. Mayo Clin Proc. 1991; 66:711-9.
24.
Doppman JL, Miller DL. Localization of parathyroid tumors in patients with asymptomatic hyperparathyroidism and no previous surgery. J Bone Miner Res. 1991; 6:S153-8.
25.
Johnston LB, Carroll MJ, Britton KE, Lowe DG, Shand W, Besser GM, et al. The accuracy of parathyroid gland localization in primary hyperparathyroidism using sestamibi radionuclide imaging. J Clin Endocrinol Metab. 1996; 81:346-52.
26.
Hindie E, Melllere D, Slmon D, Perlemutter L, Galle P. Primary hyperparathyroidism: is technetium 99m-sestamibi/iodine-123 subtraction scanning the best procedure to locate enlarged glands before surgery? J Clin Endocrinol Metab. 1995; 83:302-7.
27.
Lee VS, Wilkinson RH Jr, Leight GS Jr, Coogan AC, Coleman RE. Hyperparathyroidism in high risk surgical patients: evaluation with doublephase technetium-99m sestamibi imaging. Radiology. 1995; 197:627-33.
28.
Rizzoli R, Green J 3d, Marx SJ. Primary hyperparathyroidism in familial multiple endocrine neoplasia type I. Long-term follow-up of serum calcium after parathyroidectomy. Am J Med. 1985; 78:468-73.
29.
Norton JA, Doppman JL, Jensen RT. Curative resection in Zollinger-Ellison syndrome. Results of a 10-year prospective study. Ann Surg. 1992; 215:8-18.
30.
Weber HC, Venzon DJ, Lin JT, Fishbein VA, Orbuch M, Strader DB, et al. Determinants of metastatic rate and survival of patients with Zollinger-Ellison syndromes: a prospective long-term study. Gastroenterology. 1995; 108:1637-49.
31.
Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ, Termanini B, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med. 1996; 125:26-34.
32.
Doppman JL, Chang R, Fraker DL, Norton JA, Alexander HR, Miller DL, et al. Localization of insulinomas to regions of the pancreas by intra-arterial stimulation with calcium. Ann Intern Med. 1995; 123:269-73.
33.
Oldfield EH, Doppman JL, Nieman LK, Chrousos GP, Miller DL, Katz DA, et al. Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing's syndrome. N Engl J Med. 1991; 325:897-905.
34.
Ram Z, Shawker TH, Bradford MH, Doppman JL, Oldfield EH. Intraoperative ultrasound-directed resection of pituitary tumors. J Neurosurg. 1995; 83:225-30.
35.
Ott J. Analysis of Human Genetic Linkage. Baltimore: Johns Hopkins Univ Pr; 1991.
36.
Kytola S, Leisti J, Winqvist R, Salmela P. Improved carrier testing for multiple endocrine neoplasia, type 1, using new microsatellite-type DNA markers. Hum Genet. 1995; 96:449-53.
37.
Smith CM, Wells SA, Gearhard DS. Mapping eight new polymorphisms in 11q13 in the vicinity of multiple endocrine neoplasia type 1: identification of a new distal recombinant. Hum Genet. 1995; 96:377-87.
38.
Guru SC, Olufemi SE, Manickam P, Cummings C, Gieser LM, Pike BL, et al. A 2.8-Mb clone contig of the multiple endocrine neoplasia type 1 (MEN1) region at 11q13. Genomics. 1997; 42:436-45.
39.
Manickam P, Guru SC, Debelenko LV, Agarwal SK, Olufemi SE, Weisemann JM, et al. Eighteen new polymorphic markers in the multiple endocrine neoplasia type 1 (MEN1) region. Hum Genet. 1997; 101:102-8.
40.
Courseaux A, Grosgeorge J, Gaudray P, Pannett AA, Forbes SA, Williamson D, et al. Definition of the minimal MEN1 candidate are based on a 5-Mb integrated map of proximal 11q13. The European Consortium on MEN1 (GENEM 1, Groupe d'Etude des Neoplasies Endocriniennes Multiples de type 1). Genomics. 1996; 37:354-65.
41.
Debelenko LV, Emmert-Buck MR, Manickam P, Kester M, Guru SC, DiFranco EM, et al. Haplotype analysis defines a new minimal interval for the multiple endocrine neoplasia type 1 (MEN1) gene. Cancer Res. 1997; 57:1039-42.
42.
Guru SC, Agarwal SK, Manickam P, Olufemi SE, Crabtree JS, Weisemann J, et al. A transcript map for the 2.8-Mb region containing the multiple endocrine neoplasia type 1 locus [Letter]. Genome Res. 1997; 7:725-35.
43.
Emmert-Buck MR, Bonner RF, Smith PD, Chuaqui RF, Zhuang Z, Goldstein SR, et al. Laser capture microdissection. Science. 1996; 274:998-1001.
44.
Lubensky IA, Debelenko LV, Zhuang Z, Emmert-Buck MR, Dong Q, Chandrasekharappa S, et al. Allelic deletions in chromosome 11q13 in multiple tumors from individual MEN1 patients. Cancer Res. 1996; 56:5272-8.
45.
Emmert-Buck MR, Lubensky IA, Dong Q, Manickam P, Guru SC, Kester MB, et al. Localization of the multiple endocrine neoplasia type 1 (MEN1) gene based on tumor loss of heterozygosity analysis. Cancer Res. 1997; 57:1855-8.
46.
Collins FS. Positional cloning moves from perditional to traditional. Nat Genet. 1995; 9:347-50.
47.
Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, et al. Positional cloning of the gene for multiple endocrine neoplasia type 1. Science. 1997; 276:404-7.
48.
Agarwal SK, Kester MB, Debelenko LV, Heppner C, Emmert-Buck MR, Skarulis MC, et al. Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum Mol Genet. 1997; 7:1169-75.
49.
Lemmens I, Van de Ven WJ, Kas K, Zhang CX, Giraud S, Wautot V, et al. Identification of the multiple endocrine neoplasia type 1 (MEN1) gene. The European Consortium on MEN1. Hum Molec Genet. 1997; 7:1177-83.
50.
Mayr B, Apenberg S, Rothamel T, von zur Muhlen A, Brabant G. Menin mutations in patients with multiple endocrine neoplasia type 1. Eur J Endocrinol. 1997; 137:684-7.
51.
Tanaka C, Yoshimoto K, Yamada S, Nishioka H, li S, Moritani M, et al. Absence of germ-line mutations of the multiple endocrine neoplasia type 1 (MEN1) gene in familial pituitary adenoma in contrast to MEN1 in Japanese. J Clin Endocrinol Metab. 1998; 83:960-5.
52.
Olufemi SE, Green JS, Manickam P, Guru SC, Agarwal SK, Kester MB, et al. A common ancestral mutation in the MEN1 gene is likely responsible for the prolactinoma variant (MEN1Burin) in four kindreds from Newfoundland. Hum Mutat. 1998; 11:264-9.
53.
Heppner C, Kester MB, Agarwal SK, Debelenko LV, Emmert-Buck MR, Guru SC, et al. Somatic mutation of the MEN1 gene in parathyroid tumours. Nat Genet. 1997; 16:375-8.
54.
Zhuang Z, Vortmeyer AO, Pack S, Huang S, Pham TA, Wang C, et al. Somatic mutations of the MEN1 tumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res. 1997; 57:4682-6.
55.
Debelenko LV, Brambilla E, Agarwal SK, Swalwell JI, Kester MB, Lubensky IA, et al. Identification of MEN1 gene mutations in sporadic carcinoid tumors of the lung. Hum Mol Genet. 1997; 6:2285-90.
56.
Zhuang Z, Ezzat SZ, Vortmeyer AO, Weil R, Oldfield EH, Park WS, et al. Mutations of the MEN1 tumor suppressor gene in pituitary tumors. Cancer Res. 1997; 57:5446-51.
57.
Beaudet AL, Tsui L. A suggested nomenclature for designating mutations. Hum Mutat. 1993; 2:245-8.
58.
Bassett JH, Forbes SA, Pannett AA. Lloyd SE, Christie PT, Wooding C, et al. Characterization of mutations in patients with multiple endocrine neoplasia type 1. Am J Hum Genet. 1998; 62:232-44.
59.
Guru SC, Goldsmith PK, Burns AL, Marx SJ, Spiegel AM, Collins FS, et al. Menin, the product of the MEN1 gene, is a nuclear protein. Proc Natl Acad Sci U S A. 1998; 95:1630-4.
60.
Points to consider: ethical, legal, and psychosocial implications of genetic testing in children and adolescents. American Society of Human Genetics Board of Directors, American College of Medical Genetics Board of Directors. Am J Hum Genet. 1995; 57:1233-41.

Information & Authors

Information

Published In

cover image Annals of Internal Medicine
Annals of Internal Medicine
Volume 129Number 615 September 1998
Pages: 484 - 494

History

Published in issue: 15 September 1998
Published online: 15 August 2000

Keywords

Authors

Affiliations

Stephen Marx, MD
Moderator (Marx)
Discussants (Spiegel, Skarulis, Doppman, Collins, Liotta)
For definitions of terms used, see Glossary at end of text.
An edited summary of a Clinical Staff Conference held on 4 June 1997 at the National Institutes of Health, Bethesda, Maryland.
Authors who wish to cite a section of the conference and specifically indicate its author may use this example for the form of the reference:
Skarulis MC. Clinical expressions of multiple endocrine neoplasia type 1 at the National Institutes of Health. pp 486-487. In: Marx S, moderator. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med. 1998; 129:484-494.
Allen M. Spiegel, MD
Moderator (Marx)
Discussants (Spiegel, Skarulis, Doppman, Collins, Liotta)
For definitions of terms used, see Glossary at end of text.
An edited summary of a Clinical Staff Conference held on 4 June 1997 at the National Institutes of Health, Bethesda, Maryland.
Authors who wish to cite a section of the conference and specifically indicate its author may use this example for the form of the reference:
Skarulis MC. Clinical expressions of multiple endocrine neoplasia type 1 at the National Institutes of Health. pp 486-487. In: Marx S, moderator. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med. 1998; 129:484-494.
Monica C. Skarulis, MD
Moderator (Marx)
Discussants (Spiegel, Skarulis, Doppman, Collins, Liotta)
For definitions of terms used, see Glossary at end of text.
An edited summary of a Clinical Staff Conference held on 4 June 1997 at the National Institutes of Health, Bethesda, Maryland.
Authors who wish to cite a section of the conference and specifically indicate its author may use this example for the form of the reference:
Skarulis MC. Clinical expressions of multiple endocrine neoplasia type 1 at the National Institutes of Health. pp 486-487. In: Marx S, moderator. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med. 1998; 129:484-494.
John L. Doppman, MD
Moderator (Marx)
Discussants (Spiegel, Skarulis, Doppman, Collins, Liotta)
For definitions of terms used, see Glossary at end of text.
An edited summary of a Clinical Staff Conference held on 4 June 1997 at the National Institutes of Health, Bethesda, Maryland.
Authors who wish to cite a section of the conference and specifically indicate its author may use this example for the form of the reference:
Skarulis MC. Clinical expressions of multiple endocrine neoplasia type 1 at the National Institutes of Health. pp 486-487. In: Marx S, moderator. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med. 1998; 129:484-494.
Francis S. Collins, MD, PhD
Moderator (Marx)
Discussants (Spiegel, Skarulis, Doppman, Collins, Liotta)
For definitions of terms used, see Glossary at end of text.
An edited summary of a Clinical Staff Conference held on 4 June 1997 at the National Institutes of Health, Bethesda, Maryland.
Authors who wish to cite a section of the conference and specifically indicate its author may use this example for the form of the reference:
Skarulis MC. Clinical expressions of multiple endocrine neoplasia type 1 at the National Institutes of Health. pp 486-487. In: Marx S, moderator. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med. 1998; 129:484-494.
Lance A. Liotta, MD, PhD
Moderator (Marx)
Discussants (Spiegel, Skarulis, Doppman, Collins, Liotta)
For definitions of terms used, see Glossary at end of text.
An edited summary of a Clinical Staff Conference held on 4 June 1997 at the National Institutes of Health, Bethesda, Maryland.
Authors who wish to cite a section of the conference and specifically indicate its author may use this example for the form of the reference:
Skarulis MC. Clinical expressions of multiple endocrine neoplasia type 1 at the National Institutes of Health. pp 486-487. In: Marx S, moderator. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann Intern Med. 1998; 129:484-494.
Acknowledgments: The authors thank major collaborators, including Sunita K. Agarwal, Mary Beth Kester, Christina Heppner, Young S. Kim, Paul K. Goldsmith, and A. Lee Burns (all from the National Institute of Diabetes and Digestive and Kidney Disease [NIDDK]); Sirandanahalli C. Guru, Pachiappan Manickam, Shodimu-Emmanuel Olufemi, Judith Crabtree, and Settara C. Chandrasekharappa (all from the National Institute of Human Genome Research); Larissa V. Debelenko, Zhengping Zhuang, Irina A. Lubensky, and Michael R. Emmert-Buck (all from the National Cancer Institute); Mark Boguski and Jane Weisemann (both from the National Center for Biotechnology Information); Bruce Roe and Yingping Wang (both from the University of Oklahoma); and Jane S. Green (from Memorial University, Newfoundland, Canada). The authors also thank Lee S. Weinstein, William F. Simonds, and many current and former staff members and fellows in the NIDDK/National Institute of Child Health and Development Interinstitute Endocrine Fellowship Program and in the National Cancer Institute Surgery Branch.
Corresponding Author: Stephen J. Marx, MD, Building 10, Room 9C-101, National Institutes of Health, Bethesda, MD 20892.
Current Author Addresses: Dr. Marx: National Institutes of Health, Building 10, Room 9C-101, Bethesda, MD 20892.

Metrics & Citations

Metrics

Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. For an editable text file, please select Medlars format which will download as a .txt file. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format





Download article citation data for:
Stephen Marx, Allen M. Spiegel, Monica C. Skarulis, et al. Multiple Endocrine Neoplasia Type 1: Clinical and Genetic Topics. Ann Intern Med.1998;129:484-494. doi:10.7326/0003-4819-129-6-199809150-00011

View More

Get Access

Login Options:
Purchase

You will be redirected to acponline.org to sign-in to Annals to complete your purchase.

Access to EPUBs and PDFs for FREE Annals content requires users to be registered and logged in. A subscription is not required. You can create a free account below or from the following link. You will be redirected to acponline.org to create an account that will provide access to Annals. If you are accessing the Free Annals content via your institution's access, registration is not required.

Create your Free Account

You will be redirected to acponline.org to create an account that will provide access to Annals.

View options

PDF/ePub

View PDF/ePub

Related in ACP Journals

Full Text

View Full Text

Media

Figures

Other

Tables

Share

Share

Copy the content Link

Share on social media